Stocktoria
Zhengye Biotechnology Holding Ltd ZYBT
Zhengye Biotechnology Holding Ltd (ZYBT) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the grey zone. It pays a dividend (safety: no dividend). FY2025 revenue was $16.6M at a -60.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.08 — grey zone (between the usual thresholds). A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.039 |
| Retained earnings / assets | -0.05 |
| EBIT / assets | -0.162 |
| Equity / liabilities | 2.363 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ZYBT | Zhengye Biotechnology Holding Ltd | 4/9 | 1.49 | — | -91.1% |
| QURE | uniQure N.V. | 4/9 | -1.71 | — | -40.6% |
| NEUP | Neuphoria Therapeutics Inc. | 4/9 | -16.04 | — | — |
| CNTA | Centessa Pharmaceuticals plc | 4/9 | -1.11 | — | — |
| IRD | Opus Genetics, Inc. | 3/9 | -11.42 | — | +29.1% |
| ABUS | Arbutus Biopharma Corp | 3/9 | — | — | — |
| SLGL | Sol-Gel Technologies Ltd. | 5/9 | -19.59 | — | +68% |
About Zhengye Biotechnology Holding Ltd
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. It also develops vaccines for household animals, including rabies vaccine and Strain Flury LEP for dogs. In addition, the company exports its products to Vietnam, Pakistan, and Egypt. It serves direct-end customers, including livestock farmers and local governments; and domestic distributors and exporting distributors. The company was incorporated in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.
FAQ
Is ZYBT financially healthy?
Zhengye Biotechnology Holding Ltd's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does ZYBT pay a dividend, and is it safe?
Yes. Zhengye Biotechnology Holding Ltd pays a dividend with a None payout ratio, rated “no dividend” for safety.
How profitable is ZYBT?
In FY2025, Zhengye Biotechnology Holding Ltd had a net margin of -60.0% and a return on equity of -22.8%.
Is ZYBT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Zhengye Biotechnology Holding Ltd: a Piotroski F-score of 4/9, an Altman Z″ in the grey zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.